Enlaza Therapeutics secures $100m in Series A funding

2024-05-01

蛋白降解靶向嵌合体

Enlaza Therapeutics secures $100m in Series A funding

Preview

来源: Pharmaceutical Technology

Enlaza’s platform is designed to produce therapeutic warheads that can covalently attach to drug targets. Credit: Mongkolchon Akesin / Shutterstock.com.

Enlaza Therapeutics has raised $100m in a Series A financing round headed by the Life Sciences group of JP Morgan Asset Management’s private capital division.

The funding round also saw contributions from a mix of existing and new investors, including Frazier Life Sciences, Lightspeed Venture Partners, Avalon Ventures, Samsara BioCapital and Amgen Ventures.

The funds will be channelled towards the development of Enlaza’s covalent protein technologies and will propel its wholly owned pipeline programmes towards clinical trials.

JP Morgan private capital life sciences group chief investment officer Stephen Squinto has joined the board of directors of Enlaza.

War-Lock, the company’s covalent biologic platform, produces highly specific therapeutic warheads which covalently attach to drug targets. This may lead to improved efficacy and reduced toxicities by minimising peripheral exposure.

See Also:Bayer and Evotec link to develop precision cardiology therapeutics

Preview

来源: Pharmaceutical Technology

Corcept Therapeutics gets grant for method of preparing compound of formula i

Preview

来源: Pharmaceutical Technology

The War-Lock platform is versatile, with the potential for wide-ranging applications including the production of therapeutic candidates exhibiting excellent drug-like properties.

The platform’s protein drugs can be tailored with varied payloads, ensuring targeted delivery to specific tissues with high precision.

Enlaza also shared promising preclinical data for its oncology drug candidates. The data underscore the covalent mechanism of action, demonstrating efficient tumour penetration, rapid systemic clearance, high tumour retention and minimal off-target liabilities.

Enlaza Therapeutics CEO Sergio Duron stated: “We are thrilled to close this financing with a group of new and existing investors that share our vision of creating a novel, differentiated class of protein therapeutics in oncology and other therapeutic areas.

“This support will enable continued expansion of our covalent protein drug platform, [the] establishment of a diversified pipeline that demonstrates the broad potential of this approach, and advancement of our lead assets toward clinical development.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构